GPCR
Structure Therapeutics Inc.
+0.15 (+0.42%)35.65USD346K成交股數7.6B市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-05下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 0.00 |
| 近 180 天 淨額 | 0.00 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | 09-02 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 17.8K | – | – | 229K | SEC |
| 2026-09-01 | 09-02 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 17.8K | 0.34 | 6K | 247K | SEC |
| 2026-08-18 | 08-19 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 11.8K | 0.34 | 4K | 241K | SEC |
| 2026-08-18 | 08-19 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 11.8K | – | – | 229K | SEC |
| 2026-08-06 | 08-07 | Berrios John Joseph | Chief Commercial Officer | A 獲配股票 | 141K | – | – | 141K | SEC |
| 2026-08-04 | 08-05 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 11.8K | 0.34 | 4K | 241K | SEC |
| 2026-08-04 | 08-05 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 11.8K | – | – | 229K | SEC |
| 2026-07-14 | 07-15 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 23.6K | 0.34 | 8K | 253K | SEC |
| 2026-07-14 | 07-15 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 23.6K | – | – | 229K | SEC |
| 2026-06-25 | 06-29 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 23.6K | 0.34 | 8K | 253K | SEC |
| 2026-06-25 | 06-29 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 23.6K | – | – | 229K | SEC |
| 2026-04-15 | 04-23 | Lang Matthew | COO & GC | A 獲配股票 | 185K | – | – | 185K | SEC |
| 2026-03-19 | 03-23 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | A 獲配股票 | 260K | – | – | 1.4M | SEC |
| 2026-03-19 | 03-23 | Hall Ashley | Chief Development Officer | A 獲配股票 | 47.7K | – | – | 155K | SEC |
| 2026-03-19 | 03-23 | Yoon Jun | CHIEF FINANCIAL OFFICER | A 獲配股票 | 104K | – | – | 1.4M | SEC |
| 2026-03-19 | 03-23 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | A 獲配股票 | 43.4K | – | – | 229K | SEC |
| 2026-03-19 | 03-23 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | A 獲配股票 | 32.5K | – | – | 140K | SEC |
| 2026-03-19 | 03-23 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | A 獲配股票 | 75.9K | – | – | 281K | SEC |
| 2026-03-03 | 03-05 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | F 繳稅扣股 | 53.5K | 20.99 | 1.1M | 1.1M | SEC |
| 2026-03-03 | 03-05 | Hall Ashley | Chief Development Officer | F 繳稅扣股 | 4.8K | 20.99 | 102K | 107K | SEC |
| 2026-03-03 | 03-05 | Yoon Jun | CHIEF FINANCIAL OFFICER | F 繳稅扣股 | 22.3K | 20.99 | 468K | 1.3M | SEC |
| 2026-03-03 | 03-05 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | F 繳稅扣股 | 18.7K | 20.99 | 393K | 186K | SEC |
| 2026-03-03 | 03-05 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | F 繳稅扣股 | 11.3K | 20.99 | 237K | 107K | SEC |
| 2026-03-03 | 03-05 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | F 繳稅扣股 | 11.8K | 20.99 | 248K | 205K | SEC |
| 2025-09-18 | 09-22 | Hall Ashley | Chief Development Officer | F 繳稅扣股 | 6.0K | 7.74 | 47K | 112K | SEC |
| 2025-09-18 | 09-22 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | F 繳稅扣股 | 8.1K | 7.74 | 63K | 217K | SEC |
| 2025-07-01 | 08-20 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | F 繳稅扣股 | 4.5K | 6.84 | 31K | 119K | SEC |
| 2025-07-01 | 08-20 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | F 繳稅扣股 | 12.8K | 6.84 | 88K | 204K | SEC |
| 2025-07-01 | 07-03 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | A 獲配股票 | 89.7K | – | – | 1.2M | SEC |
| 2025-07-01 | 07-03 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | A 獲配股票 | 24.5K | – | – | 123K | SEC |
| 2025-07-01 | 07-03 | Yoon Jun | CHIEF FINANCIAL OFFICER | A 獲配股票 | 39.6K | – | – | 1.3M | SEC |
| 2025-07-01 | 07-03 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | A 獲配股票 | 8.0K | – | – | 226K | SEC |
| 2025-07-01 | 07-03 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | F 繳稅扣股 | 1.4K | 6.84 | 10K | 225K | SEC |
| 2025-07-01 | 07-03 | Yoon Jun | CHIEF FINANCIAL OFFICER | F 繳稅扣股 | 7.1K | 6.84 | 48K | 1.3M | SEC |
| 2025-07-01 | 07-03 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | F 繳稅扣股 | 16.1K | 6.84 | 110K | 1.2M | SEC |
| 2025-07-01 | 07-03 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | A 獲配股票 | 57.1K | – | – | 217K | SEC |
| 2025-03-15 | 03-18 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | A 獲配股票 | 340K | – | – | 1.1M | SEC |
| 2025-03-15 | 03-18 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | A 獲配股票 | 80.8K | – | – | 167K | SEC |
| 2025-03-15 | 03-18 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | A 獲配股票 | 63.8K | – | – | 101K | SEC |
| 2025-03-15 | 03-18 | Hall Ashley | Chief Development Officer | A 獲配股票 | 51.0K | – | – | 118K | SEC |
| 2025-03-15 | 03-18 | Coll Crespo Blas | Chief Medical Officer | A 獲配股票 | 117K | – | – | 220K | SEC |
| 2025-03-15 | 03-18 | Yoon Jun | CHIEF FINANCIAL OFFICER | A 獲配股票 | 170K | – | – | 1.3M | SEC |
| 2025-03-01 | 07-03 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | F 繳稅扣股 | 12.5K | 7.92 | 99K | 1.1M | SEC |
| 2025-03-01 | 07-03 | Yoon Jun | CHIEF FINANCIAL OFFICER | F 繳稅扣股 | 5.9K | 7.92 | 47K | 1.3M | SEC |
| 2025-03-01 | 07-03 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | F 繳稅扣股 | 6.4K | 7.92 | 51K | 160K | SEC |
| 2025-03-01 | 07-03 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | F 繳稅扣股 | 1.8K | 7.92 | 14K | 98.7K | SEC |
| 2025-03-01 | 07-03 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | F 繳稅扣股 | 1.2K | 7.92 | 10K | 218K | SEC |
| 2024-09-18 | 09-20 | Coll Crespo Blas | Chief Medical Officer | A 獲配股票 | 90.6K | – | – | 103K | SEC |
| 2024-09-18 | 09-20 | Hall Ashley | Chief Development Officer | A 獲配股票 | 67.3K | – | – | 67.3K | SEC |
| 2024-06-12 | 06-14 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | M 選擇權執行 | 100.0K | 0.39 | 39K | 743K | SEC |
| 2024-06-12 | 06-14 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | M 選擇權執行 | 50.0K | 0.48 | 24K | 793K | SEC |
| 2024-06-10 | 06-12 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | C 轉換 | 555K | – | – | 643K | SEC |
| 2024-06-03 | 06-05 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | M 選擇權執行 | 106K | 0.34 | 36K | 192K | SEC |
| 2024-06-03 | 06-05 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | C 轉換 | 106K | – | – | 85.7K | SEC |
| 2024-03-15 | 03-19 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | A 獲配股票 | 135K | – | – | 1.2M | SEC |
| 2024-03-15 | 03-19 | Yoon Jun | CHIEF FINANCIAL OFFICER | A 獲配股票 | 59.5K | – | – | 1.1M | SEC |
| 2024-03-15 | 03-19 | Bach Mark Allen | CHIEF MEDICAL OFFICER | A 獲配股票 | 26.2K | – | – | 26.2K | SEC |
| 2024-03-15 | 03-19 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | A 獲配股票 | 36.7K | – | – | 36.7K | SEC |
| 2024-03-15 | 03-19 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | A 獲配股票 | 85.7K | – | – | 85.7K | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND L P | Other | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND L P | Other | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND L P | Other | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF PARTNERS L P/IL | TenPercentOwner | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF PARTNERS L P/IL | TenPercentOwner | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF PARTNERS L P/IL | TenPercentOwner | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF INC/IL | TenPercentOwner | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF INC/IL | TenPercentOwner | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF INC/IL | TenPercentOwner | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND II LP | Other | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND II LP | Other | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BIOTECHNOLOGY VALUE FUND II LP | Other | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | LAMPERT MARK N | TenPercentOwner | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | LAMPERT MARK N | TenPercentOwner | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | LAMPERT MARK N | TenPercentOwner | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | Biotechnology Value Trading Fund OS LP | Other | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | Biotechnology Value Trading Fund OS LP | Other | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | Biotechnology Value Trading Fund OS LP | Other | J 其他 | 463K | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF Partners OS Ltd. | Other | J 其他 | 4.0M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF Partners OS Ltd. | Other | J 其他 | 2.9M | – | – | 0 | SEC |
| 2023-05-10 | 05-12 | BVF Partners OS Ltd. | Other | J 其他 | 463K | – | – | 0 | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 7.8M | 419M | 新進 | 新進 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.4M | 396M | 新進 | 新進 |
| Avoro Capital Advisors LLC | 6.6M | 352M | 新進 | 新進 |
| Jupiter Topco LLC | 5.2M | 279M | 新進 | 新進 |
| Deep Track Capital, LP | 4.7M | 254M | 新進 | 新進 |
| BVF INC/IL | 3.4M | 181M | 新進 | 新進 |
| MORGAN STANLEY | 2.8M | 151M | 新進 | 新進 |
| ORBIMED ADVISORS LLC | 2.2M | 119M | 新進 | 新進 |
| PRINCIPAL FINANCIAL GROUP INC | 1.8M | 94.1M | 新進 | 新進 |
| AMERICAN CENTURY COMPANIES INC | 1.7M | 90.3M | 新進 | 新進 |
| RTW INVESTMENTS, LP | 1.6M | 86.3M | 新進 | 新進 |
| Driehaus Capital Management LLC | 1.6M | 83.4M | 新進 | 新進 |
| BAKER BROS. ADVISORS LP | 1.4M | 76.9M | 新進 | 新進 |
| Casdin Capital, LLC | 1.2M | 63.1M | 新進 | 新進 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.1M | 58.3M | 新進 | 新進 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 1.0M | 55.9M | 新進 | 新進 |
| Siren, L.L.C. | 873K | 46.9M | 新進 | 新進 |
| Pacific Heights Asset Management LLC | 800K | 42.9M | 新進 | 新進 |
| Rock Springs Capital Management LP | 640K | 34.4M | 新進 | 新進 |
| Aberdeen Group plc | 640K | 34.3M | 新進 | 新進 |
| FRANKLIN RESOURCES INC | 579K | 31.1M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 563K | 30.2M | 新進 | 新進 |
| ALLIANCEBERNSTEIN L.P. | 612K | 29.5M | 新進 | 新進 |
| BlackRock, Inc. | 511K | 27.4M | 新進 | 新進 |
| Logos Global Management LP | 500K | 26.8M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 192 -4 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 192 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 67.6M · 31.6% |
| 合計季末市值 | 3.6B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 5.9M |
|---|---|
| 與上期比 | -3.7% |
| 佔流通股數 | 2.74% |
| 日均成交量 | 740K |
| 回補天數 | 7.9 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 5.9M | -3.7% | 2.74% | 740K | 7.9 |
| 2026-08-14 | 6.1M | +0.5% | 2.84% | 586K | 10.4 |
| 2026-07-31 | 6.0M | -2.5% | 2.83% | 529K | 11.5 |
| 2026-07-15 | 6.2M | +1.3% | 2.90% | 703K | 8.8 |
| 2026-06-30 | 6.1M | +4.0% | 2.86% | 978K | 6.3 |
| 2026-06-15 | 5.9M | +5.8% | 2.76% | 826K | 7.1 |
| 2026-05-29 | 5.6M | -1.4% | 2.60% | 618K | 9.0 |
| 2026-05-15 | 5.7M | -5.4% | 2.64% | 771K | 7.3 |
| 2026-04-30 | 6.0M | -2.8% | 2.79% | 884K | 6.8 |
| 2026-04-15 | 6.1M | +6.8% | 2.87% | 1.0M | 6.1 |
| 2026-03-31 | 5.8M | +9.4% | 2.69% | 1.2M | 4.7 |
| 2026-03-13 | 5.3M | +0.6% | 2.46% | 742K | 7.1 |
| 2026-02-27 | 5.2M | +6.1% | 2.45% | 751K | 7.0 |
| 2026-02-13 | 4.9M | -3.9% | 2.31% | 1.0M | 4.9 |
| 2026-01-30 | 5.1M | -17.8% | 2.40% | 1.1M | 4.8 |
| 2026-01-15 | 6.2M | +3.3% | 2.92% | 1.3M | 4.8 |
| 2025-12-31 | 6.0M | +23.7% | 2.83% | 1.1M | 5.5 |
| 2025-12-15 | 4.9M | +1.6% | 2.28% | 3.3M | 1.5 |
| 2025-11-28 | 4.8M | -9.0% | 2.25% | 1.5M | 3.2 |
| 2025-11-14 | 5.3M | -1.4% | 2.47% | 985K | 5.4 |
| 2025-10-31 | 5.4M | +10.5% | 2.50% | 766K | 7.0 |
| 2025-10-15 | 4.8M | -23.9% | 2.27% | 1.1M | 4.5 |
| 2025-09-30 | 6.4M | -6.3% | 2.98% | 1.1M | 6.0 |
| 2025-09-15 | 6.8M | -2.1% | 3.18% | 1.6M | 4.2 |
| 2025-08-29 | 6.9M | -4.4% | 3.24% | 587K | 11.8 |
| 2025-08-15 | 7.3M | +0.9% | 3.39% | 1.1M | 6.8 |